Skip to main content

Regeneron Still Has Legs: Leerink Targets $630 a Share

Leerink analysts Jason Schwartz and Mayank Mamtani have joined the other biotech industry pundits proclaiming that Regeneron Pharmaceuticals’ (REGN) run isn’t over. The pair raised their price target on the high-flying biotech stock to $630 from $559, partly to reflect last week’s FDA approval of the high cholesterol drug Praluent Schwartz and Mamtani see sales [...]
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.